Reconsideration of Interactions Between Direct Oral Anticoagulants and Calcineurin Inhibitors

  • Zohre Labbani-Motlagh School of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
  • Simin Dashti-Khavidaki Mail Department of Clinical Pharmacy, School of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
Keywords:
No Keywords

Abstract

No abstract  No abstract

 

References

1. Steffel J, Verhamme P, Potpara TS, et al. The 2018 european heart rhythm association practical guide on the use of non-vitamin k antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J 2018;39(16):1330-93.
2. De Jonge H, De Loor H, Verbeke K, Vanrenterghem Y, Kuypers D. In vivo CYP3A activity is significantly lower in cyclosporine‐treated as compared with tacrolimus‐treated renal allograft recipients. Clin Pharmacol Ther 2011;90(3):414-22.
3. Lemahieu W, Maes B, Verbeke K, Vanrenterghem Y. CYP3A4 and P‐glycoprotein activity in healthy controls and transplant patients on cyclosporin vs. tacrolimus vs. sirolimus. Am J Transplant 2004;4(9):1514-22.
4. Lam E, Bashir B, Chaballa M, Kraft WK. Drug interactions between direct-acting oral anticoagulants and calcineurin inhibitors during solid organ transplantation: considerations for therapy. Expert Rev Clin Pharmacol 2019;12(8):781-90.
5. Alsheikh R, Alfayez OM, Al Yami MS. Insights from practice with use of direct oral anticoagulants in transplantation. Prog Transplant 2018;28(4):380-5.
6. Vanhove T, Spriet I, Annaert P, et al. Effect of the direct oral anticoagulants rivaroxaban and apixaban on the disposition of calcineurin inhibitors in transplant recipients. Ther Drug Monit 2017;39(1):77-82.
Published
2020-06-26
How to Cite
1.
Labbani-Motlagh Z, Dashti-Khavidaki S. Reconsideration of Interactions Between Direct Oral Anticoagulants and Calcineurin Inhibitors. J Pharm Care. 8(2):88-89.
Section
Letter to the Editor